General Information of Drug (ID: DMCEY6O)

Drug Name
3,5-dibromo-2-(2,4-dibromophenoxy)phenol Drug Info
Synonyms
3,5-Dibromo-2-(2,4-dibromophenoxy)phenol; CHEMBL258224; 79755-43-4; BPE-5; AC1MJ5LD; AC1Q78K6; 6-OH-BDE47; DTXSID60229856; ZINC14676777; SR-1-1; BDBM50232491; 6-Hydroxy-2,2,4,4-tetrabromodiphenyl ether; 6-hydroxy-2,2',4,4'-tetrabromodiphenylether; 3,5-dibromo-2-(2'',4''-dibromophenoxy)phenol; Phenol, 3,5-dibromo-2-(2,4-dibromophenoxy)-
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3086109
CAS Number
CAS 79755-43-4
TTD Drug ID
DMCEY6O

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyrophosphate 2- DMZQ75M Discovery agent N.A. Investigative [3]
2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol DMQYEZP Discovery agent N.A. Investigative [1]
Decoyinine DMHO3N1 Discovery agent N.A. Investigative [4]
3,4,5-tribromo-2-(2', 4'-dibromo-phenoxy)phenol DMS42CA Discovery agent N.A. Investigative [1]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Leuprolide DM5XPIJ Plasma cell myeloma 2A83.1 Approved [5]
Quercetin DM3NC4M Obesity 5B81 Approved [6]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [2]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [7]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [8]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [9]
Azathioprine DMMZSXQ Lupus nephritis 4A40.0Y Approved [10]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [11]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [12]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamine amidotransferase (GMPS) TTCFP0V GUAA_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Thyroxine-binding globulin (SERPINA7) OTUYVTSU THBG_HUMAN Protein Interaction/Cellular Processes [2]
Transthyretin OTAFXQRA TTHY_HUMAN Protein Interaction/Cellular Processes [2]

References

1 Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. J Nat Prod. 1995 Sep;58(9):1384-91.
2 Structure-based investigation on the binding interaction of hydroxylated polybrominated diphenyl ethers with thyroxine transport proteins. Toxicology. 2010 Nov 9;277(1-3):20-8. doi: 10.1016/j.tox.2010.08.012. Epub 2010 Sep 8.
3 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
4 High-level production from a baculovirus expression system and biochemical characterization of human GMP synthetase. Protein Expr Purif. 1995 Aug;6(4):487-95.
5 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
7 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
8 Thyroid function and plasma concentrations of polyhalogenated compounds in Inuit adults. Environ Health Perspect. 2009 Sep;117(9):1380-6. doi: 10.1289/ehp.0900633. Epub 2009 May 12.
9 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
10 A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
11 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
12 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.